

<http://www.globenewswire.com/newsroom/news.html?d=206663>

Source: LDV Capital Management

### **GenSpera to Present at the 2010 South Florida Biotech Dinner Conference**

FORT LAUDERDALE, Fla., Nov. 10, 2010 (GLOBE NEWSWIRE) -- GenSpera, Inc. (OTCBB:**GNSZ**), a development stage oncology company focused on therapeutics that delivers a unique patented drug directly to tumors, will be making a corporate dinner presentation at 6:15 p.m. on Wednesday, November 10<sup>th</sup>, before money managers and accredited investors at the South Florida Biotechnology Dinner Conference at DeerCreek Country, Club in Deerfield Beach, Florida.

The event will be hosted by LDV Capital Management, a Registered Investment Advisory firm licensed with the state of Florida. LDV Capital Management President and Founder James DePelisi stated, "It is very exciting to have a company such as GenSpera present at before our dinner assembly. The medical technology with which they are working, is quite interesting, to say the least. Both the investment and the medical community should really study closer at what GenSpera is working upon,"

GenSpera will also be in town later in the week for another event, in which LDV Capital Management is a sponsor: **The Lifetech Capital Miami Medical Investors Conference, featuring the University of Miami Miller School of Medicine.** The event is Friday, November 12<sup>th</sup>, 2010 at the JW Marriot Marquis Hotel, 345 Biscayne Boulevard Way, Miami, Florida 33131. The conference will feature 24 biotechnology and medical companies. GenSpera is scheduled to speak at 10:00 a.m. <http://lifetechcapital.com/conference/index.html>.

#### **ABOUT GENSPERA:**

*GENSPERA, INC.* (OTCBB:**GNSZ**) is a development stage oncology company focused on therapeutics that deliver a potent, unique and patented drug directly to tumors. GenSpera's technology platform combines a potent, plant-derived cytotoxin (thapsigargin) with a prodrug delivery system that releases the drug only within the tumor. Unlike standard cancer drugs, thapsigargin kills cells independent of their division rate, thus making it effective at killing all fast- and slow-growing cancers and cancer stem cells. GenSpera's prodrug platform is the subject of seven issued patents with four additional patents pending. For additional information, visit: <http://www.genspera.com>.

#### **ABOUT LDV CAPITAL MANAGEMENT:**

**LDV Capital Management** is a Registered Investment Advisory firm licensed with the state of Florida specializing in Financial Advisory, Fairness Opinions, Mergers and Acquisitions, Corporate Structuring and Capital Formation. **For further information,** call LDV Capital Management at: 954-746-3117, visit [www.LdvCapitalManagement.com](http://www.LdvCapitalManagement.com), or email [Jim@LdvCapitalManagement.com](mailto:Jim@LdvCapitalManagement.com).

DISCLAIMER: LDV Capital Management is a Registered Investment Advisory firm licensed with the State of Florida. The information herein is not a solicitation to invest, but simply information compiled from company press releases and company public information. Information is believed to be reliable, but makes no representation to its accuracy or completeness. LDV does not recommend, warrant, or guarantee the success of any action taken in reliance on statements

and professional advice should be sought before making any investment decisions. LDV, nor any of its principles or employees do not hold any stock positions in any of the companies mentioned above.

CONTACT: LDV Capital Management  
954-746-3117